| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 07/13/1999 | US5922761 Methods for in vivo reduction of iron levels and compositions useful therefor |
| 07/13/1999 | US5922740 Antiinflammatory agents |
| 07/13/1999 | US5922739 Antiischemic agents |
| 07/13/1999 | US5922735 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators |
| 07/13/1999 | US5922716 Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (ampa) receptor antagonists, non-competitive n-methyl-d-aspartate (nmda) receptor antagonists |
| 07/13/1999 | US5922703 Useful for treating congestive heart failure |
| 07/13/1999 | US5922690 Having at least 2 sulfate groups per disaccharide obtained by chemical sulfation of native dermatan sulfate. |
| 07/13/1999 | US5922674 Inhibiting endothelial cell proliferation in a subject treated by with platinum coordination complex chemotherapeutic agent by simultaneous administration of erythropoietin |
| 07/13/1999 | US5922673 Method of treating hypertension in pregnant mammals |
| 07/13/1999 | US5922322 Cleaves at the gamma glycine404-alanine405 peptide bond; apply to medical equipment to inhibit thrombus formation; administering to treat restenosis post-surgery, to inhibit vascular reocclusion |
| 07/13/1999 | US5922302 Detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates |
| 07/13/1999 | CA2176037C Antithrombotic amidinophenylalanine and amidinopyridylalanine derivatives |
| 07/08/1999 | WO1999033873A1 NOVEL POLYPEPTIDES, cDNAS ENCODING THE SAME AND UTILIZATION THEREOF |
| 07/08/1999 | WO1999033849A1 Prodrugs of naaladase inhibitors |
| 07/08/1999 | WO1999033841A2 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action |
| 07/08/1999 | WO1999033840A2 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha1-blocking action |
| 07/08/1999 | WO1999033836A1 3'-epimeric k-252a derivatives |
| 07/08/1999 | WO1999033825A1 N-phenylamide and n-pyridylamide derivatives, method of preparing them and pharmaceutical compositons containing them |
| 07/08/1999 | WO1999033822A1 Indole derivatives useful a.o. for the treatment of osteoporosis |
| 07/08/1999 | WO1999033806A1 4-[aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor |
| 07/08/1999 | WO1999033800A1 Indole derivatives as inhibitors or factor xa |
| 07/08/1999 | WO1999033789A1 SUBSTITUTED β-ALANINES |
| 07/08/1999 | WO1999033476A1 Hyperhydrated citicoline, process and use |
| 07/08/1999 | WO1999033460A1 Acyl guanidine sodium/proton exchange inhibitors and method |
| 07/08/1999 | WO1999033455A1 Tetracycline and/or tetracycline derivative(s) for treating, suppressing and preventing of cerebrovascular diseases of nervous system |
| 07/08/1999 | WO1999025686B1 Cyclic amine derivatives and their use as drugs |
| 07/08/1999 | WO1999020291A3 Pharmaceutical grade ginkgo biloba |
| 07/08/1999 | CA2317090A1 Tetracycline and/or tetracycline derivative(s) for treating, suppressing and preventing of cerebrovascular diseases of nervous system |
| 07/08/1999 | CA2316989A1 Hyperhydrated citicoline, process and use |
| 07/08/1999 | CA2316385A1 Prodrugs of naaladase inhibitors |
| 07/08/1999 | CA2316382A1 N-phenylamide and n-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them |
| 07/08/1999 | CA2316352A1 Acyl guanidine sodium/proton exchange inhibitors and method |
| 07/08/1999 | CA2316341A1 4-[aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor |
| 07/08/1999 | CA2316235A1 Substituted .beta.-alanines |
| 07/08/1999 | CA2315723A1 Indole derivatives useful a.o. for the treatment of osteoporosis |
| 07/08/1999 | CA2282815A1 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action |
| 07/08/1999 | CA2282458A1 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action |
| 07/07/1999 | EP0927763A2 Novel aroA |
| 07/07/1999 | EP0927217A1 Angiogenic inhibitory compounds |
| 07/07/1999 | EP0927192A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
| 07/07/1999 | EP0927191A2 Anti-inflammatory peptides and uses thereof |
| 07/07/1999 | EP0927183A1 Spirocyclic metalloprotease inhibitors |
| 07/07/1999 | EP0927177A1 Novel benzothiophene derivatives, their preparation and use as urokinase inhibitors |
| 07/07/1999 | EP0927170A1 Piperazino derivatives as neurokinin antagonists |
| 07/07/1999 | EP0927167A1 2-phenyl benzimidazole derivatives as mcp-1 antagonists |
| 07/07/1999 | EP0927161A1 Substituted cyclic amine metalloprotease inhibitors |
| 07/07/1999 | EP0927159A1 Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications |
| 07/07/1999 | EP0927156A1 Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
| 07/07/1999 | EP0927150A1 Lipoxin compounds and their use in treating cell proliferative disorders |
| 07/07/1999 | EP0927039A1 Induction of a cellular stress response with heavy metal salts |
| 07/07/1999 | EP0927029A1 Novel methods |
| 07/07/1999 | EP0828492A4 Method for preventing intervention-associated stenosis following non-bypass, invasive interventions |
| 07/07/1999 | CN1222193A Extracellular matrix signalling molecules |
| 07/07/1999 | CN1222076A Use of green porphyrins in manufacture of medicament in treatment of atherosclerosis without purposeful irradiation of porphyrin derivatives |
| 07/07/1999 | CN1043997C 2,6-diaminopurine derivatives, its use and medicinal compsns. containing same |
| 07/07/1999 | CN1043991C Qunazoline derivatives |
| 07/06/1999 | US5919943 Inhibition of spla2 |
| 07/06/1999 | US5919904 Response regulator polypeptides; screening for bactericides |
| 07/06/1999 | US5919810 1H-indole-3-glyoxylamide sPLA2 inhibitors |
| 07/06/1999 | US5919809 3-substituted-2-oxindole derivatives |
| 07/06/1999 | US5919806 Medicines for cardiac insufficiency |
| 07/06/1999 | US5919793 Quinuclidine derivatives, squalene synthetase inhibitors, anticholesterol agents |
| 07/06/1999 | US5919789 Xanthines and their therapeutic use |
| 07/06/1999 | US5919787 Aminotetrazole derivatives useful as nitric oxide synthase inhibitors |
| 07/06/1999 | US5919778 Alzheimer*s disease |
| 07/06/1999 | US5919773 Antisense oligonucleotide modulation of raf gene expression |
| 07/06/1999 | US5919692 Ubiquitous ATP-sensitive potassium-channel genes |
| 07/06/1999 | US5919664 For screening for antibacterial compounds |
| 07/06/1999 | US5919660 Human requiem |
| 07/06/1999 | US5919637 Method for identifying reduced binding between GMP-140 and GMP-140 ligand |
| 07/06/1999 | US5919490 Stimulating blood circulation to skin |
| 07/06/1999 | US5919455 Non-antigenic branched polymer conjugates |
| 07/06/1999 | CA2177146C Heterocyclic benzenesulfonylimine derivatives as inhibitors of il-1 action |
| 07/06/1999 | CA2130762C Treatment of disease and conditions associated with macrophage infiltration |
| 07/06/1999 | CA1340633C Method and therapeutic compositions for the treatment of myocardial infarction |
| 07/01/1999 | WO1999032637A1 Human signal transduction serine/threonine kinase |
| 07/01/1999 | WO1999032615A1 Brain or heart cyclic nucleotide gated ion channel compounds and uses thereof |
| 07/01/1999 | WO1999032520A1 Method for quantitating denatured ldls |
| 07/01/1999 | WO1999032475A1 Novel sulfonamide substituted chroman derivatives useful as beta-3 adrenoreceptor agonists |
| 07/01/1999 | WO1999032460A1 Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments |
| 07/01/1999 | WO1999032452A1 Carboxyl acid substituted heterocycles as metalloproteinase inhibitors |
| 07/01/1999 | WO1999032451A1 Azepine or larger medium ring derivatives and their use as pharmaceuticals |
| 07/01/1999 | WO1999032437A1 1,3-disubstituted ureas as acat inhibitors, and method of preparing thereof |
| 07/01/1999 | WO1999032433A1 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis |
| 07/01/1999 | WO1999032150A1 Ace inhibitor-mmp inhibitor combinations |
| 07/01/1999 | WO1999032131A1 Pharmaceutical composition comprising ticlopidine and ginkgo biloba extract |
| 07/01/1999 | WO1999032129A1 Ginkgo biloba leaf extracts with a reduced 4'-o-methylpyridoxine and biflavone content |
| 07/01/1999 | WO1999032111A1 INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS |
| 07/01/1999 | WO1999032110A1 INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS |
| 07/01/1999 | WO1999032081A1 Transmucosal formulations of levosimendan |
| 07/01/1999 | WO1999031982A1 Transvascular delivery of a composition to an extravascular tissue of a mammal |
| 07/01/1999 | WO1999016741A3 Lipophilic diesters of chelating agents |
| 07/01/1999 | WO1999010014A3 Receptor-mediated gene delivery using bacteriophage vectors |
| 07/01/1999 | WO1999003817B1 Aliphatic propargylamines as cellular rescue agents |
| 07/01/1999 | DE19756848A1 Extrakte aus Blättern von Ginkgo biloba mit vermindertem Gehalt an 4'-O-Methylpyridoxin und Biflavonen Extracts from leaves of Ginkgo biloba with a reduced content of 4'-O-methyl and biflavones |
| 07/01/1999 | CA2315720A1 Inhibition of p38 kinase activity using substituted heterocyclic ureas |
| 07/01/1999 | CA2315280A1 Method for quantifying denatured ldl |
| 07/01/1999 | CA2314925A1 Novel sulfonamide substituted chroman derivatives useful as beta-3 adrenoreceptor agonists |
| 07/01/1999 | CA2314905A1 Transvascular delivery of a composition to an extravascular tissue of a mammal |
| 07/01/1999 | CA2305436A1 Ace inhibitor-mmp inhibitor combinations |